NCT02644291View on ClinicalTrials.gov

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 9, 2022

Study Completion Date

June 9, 2022

Conditions
MedulloblastomaAstrocytoma, Grade IIIGlioblastomaAnaplastic AstrocytomaBrain Stem Neoplasms, MalignantOligodendroblastomaAnaplastic OligodendrogliomaMalignant Glioma
Interventions
DRUG

Mebendazole

chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals

Trial Locations (2)

21231

Johns Hopkins University School of Medicine, Baltimore

33701

Johns Hopkins All Children's Hospital, St. Petersburg

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02644291 - Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | Biotech Hunter | Biotech Hunter